HighGravityDataCencora — Nov 5, 2025 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001140859-25-000128
Showing in the filing
Diluted weighted average shares outstanding
“~194M”
Period
FY2026
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 20
Planned investments to strengthen U.S. distr… for FY2030
“$1 billion”
Quarterly dividend
“$0.60 per common share”
Revenue for FY2026
“5% to 7% growth”
U.S. Healthcare Solutions Segment Revenue for FY2026
“5% to 7% growth”
International Healthcare Solutions Segment R… for FY2026
“6% to 8% growth”
Other Revenue for FY2026
“0% to 4% growth”
Other (1) for FY2026
“0% to 4% growth”
Adjusted operating income for FY2026
“8% to 10% growth”
U.S. Healthcare Solutions Segment (1) - Adju… for FY2026
“9% to 11% growth”
International Healthcare Solutions Segment (… for FY2026
“5% to 8% growth”
Other (1) - Adjusted operating income for FY2026
“1% to 4% decline”
Adjusted diluted earnings per share for FY2026
“$17.45 to $17.75”
Net interest expense for FY2026
“$315M to $335M”
Adjusted effective tax rate for FY2026
“20% to 21%”
Diluted weighted average shares outstanding for FY2026
“~194M”
Adjusted free cash flow for FY2026
“~$3.0B”
Capital expenditures for FY2026
“~$900M”
Adjusted operating income for the long term
“6% to 9%”
Capital deployment for the long term
“3% to 4%”
Adjusted diluted earnings per share for the long term
“9% to 13%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Healthcare Solutions Segment (1) 9% to 11% growth $3.3B International Healthcare Solutions Segment (1)(2) 5% to 8% growth $588M Other (1) 1% to 4% decline $352M Adjusted diluted earnings per share $17.45 to $17.75 $16.00 Net interest expense $315M to $335M $292M Adjusted effective tax rate 20% to 21% 20.6% Diluted weighted average shares outstanding ~194M 195.2M Adjusted free cash flow ~$3.0B $3.0B Capital expenditures ~$900M $668M (1) For further detail on fiscal 2025 revised reportable segment information, please reference Exhibit 99.2 to the Company's form 8-K dated November 5, 2025. (2) As reported and constant currency guidance. Long-Term Guidance To reflect the strength in the Company's businesses and continued execution, the Company is raising its long-term guidance for adjusted diluted EPS and adjusted operating income. Long-term guidance (1) Adjusted operating income 6% to 9% Capital deployment 3% to 4% Adjusted diluted earnings per share 9% to 13% (1) Bold numbers indicate updates to guidance ranges. Conference Call & Slide Presentation The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. A slide presentation for investors has also been posted on the Company’s website at investor.cencora.com. The dial-in number for the live call will be (833) 470-1428. From outside the United States and Canada, dial +1 (646) 844-6383. The access code for the call will be 837725. The live call will also be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log o
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.